Intercept’s OCA In NASH: ‘Modest’ Effect On Surrogate Comes With ‘Substantial’ Risks, US FDA Says

 
• By Sue Sutter
  
Unbalanced
US FDA sees an imbalance in benefit and risk with Intercept's OCA in NASH fibrosis. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers